Abstract Number: 3106 • 2015 ACR/ARHP Annual Meeting
Regulation of ASK1 Expression By microRNA-17 and Their Correlation with Rheumatoid Arthritis Pathogenesis
Background/Purpose: Aberrant expression of microRNAs (miRs) has shown to be critical for the pathogenesis of rheumatoid arthritis (RA). Apoptosis signal regulating kinase-1 (ASK1), a member…Abstract Number: 3107 • 2015 ACR/ARHP Annual Meeting
Investigating the Ameliorating Effect of Pregnancy on Rheumatoid Arthritis Using Whole Transcriptome Analysis
Background/Purpose: Pregnancy is known to induce a natural improvement of Rheumatoid Arthritis (RA) symptoms in 50-75% of patients as gestation progresses. However, the underlying mechanisms…Abstract Number: 3108 • 2015 ACR/ARHP Annual Meeting
Serum 14-3-3eta Are Elevated in Indigenous North Americans with Rheumatoid Arthritis and May Predict Imminent Synovitis in Their at-Risk First Degree Relatives
Background/Purpose: Indigenous North Americans (INA) have high prevalence rates of severe erosive rheumatoid arthritis (RA). We have established a cohort of unaffected first degree relatives…Abstract Number: 3109 • 2015 ACR/ARHP Annual Meeting
Single Cell Gene Expression in Classical Monocytes Correlates with Treatment Response Groups to TNF-Alpha Inhibition in Rheumatoid Arthritis
Background/Purpose: In management of rheumatoid arthritis (RA), initiating effective treatment as soon as possible within the so-called therapeutic “window of opportunity” is the strategy,…Abstract Number: 3110 • 2015 ACR/ARHP Annual Meeting
In the Multicenter Randomized Controlled Rotation or Change Trial, a Non-TNF Targeted Therapy Has a Higher Efficacy Than a Second Anti-TNF at 3, 6 and 12 Months
Background/Purpose: As many as one third of patients show insufficient response to their first TNF inhibitor (TNF-insufficient response, TNF-IR). The lack of efficacy of one…Abstract Number: 3111 • 2015 ACR/ARHP Annual Meeting
Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-α (GM–CSFR-α) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Modulating macrophage function through GM–CSF is a novel therapeutic approach for RA. Mavrilimumab, a fully human monoclonal antibody, which targets GM–CSFR-α, has demonstrated efficacy…Abstract Number: 3112 • 2015 ACR/ARHP Annual Meeting
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
Background/Purpose: Treatment with biologics can elicit unwanted immune responses such as antidrug antibodies (ADA), which may decrease their clinical efficacy and increase adverse events. However,…Abstract Number: 3113 • 2015 ACR/ARHP Annual Meeting
Interest of Assessing Anti-Drug Antibodies for the Choice Between a Second Anti-TNF and a Non-TNF-Targeted Biologic in Patients with Inadequate Response to a First Anti-TNF : Results from the Randomized Controlled Trial « Rotation or Change »
Background/Purpose: Anti-drug antibodies (ADAs) might result in loss of efficacy to anti-TNF. The impact of ADAs to a 1st anti-TNF on subsequent response to a…Abstract Number: 3114 • 2015 ACR/ARHP Annual Meeting
Immunogenicity of Subcutaneous and Intravenous Tocilizumab As Monotherapy or in Combination with Dmards
Background/Purpose: Intravenous (IV) and subcutaneous (SC) formulations of tocilizumab (TCZ) are available for treatment of adult RA based upon the efficacy and safety outcomes of…Abstract Number: 3115 • 2015 ACR/ARHP Annual Meeting
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials
Background/Purpose: So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders.…Abstract Number: 3116 • 2015 ACR/ARHP Annual Meeting
High Level of Inflammation Predicts the Development of Diabetes Mellitus in Patients with Psoriatic Arthritis
Background/Purpose: To estimate trends in the prevalence of diabetes mellitus (DM) in patients with psoriatic arthritis (PsA) in comparison to the general population in Ontario,…Abstract Number: 3117 • 2015 ACR/ARHP Annual Meeting
Under-Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease – an International Multicentre Study
Background/Purpose: Cardiovascular risk in patients with psoriatic disease is partly attributed to the high prevalence of traditional cardiovascular risk factors in these patients. This study…Abstract Number: 3118 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Disease Outcomes in Psoriatic Arthritis Patients By Extent of Body Surface Area Affected By Psoriasis: Results from Corrona Registry
Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis that is commonly comorbid with the skin condition, psoriasis. A major contributor to the severity…Abstract Number: 3119 • 2015 ACR/ARHP Annual Meeting
The Risk of Venous Thromboembolism in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Background/Purpose: Venous thromboembolism (VTE), the combined endpoint of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common and potentially deadly medical problem with…Abstract Number: 3120 • 2015 ACR/ARHP Annual Meeting
The Prevalence, Incidence and Management of Hypertension, Diabetes and Hyperlipidemia in Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) are associated with an increased risk for cardiovascular disease (CVD). While management of traditional CVD risk…
ACR Meeting Abstracts